Non-Muscle invasive bladder cancer (NMIBC) Market Analysis

Non-muscle invasive bladder cancer (NMIBC) formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.

The total diagnosed prevalent population of NMIBC in the seven major markets ranges was 533,263 in 2017, which will increase for the study period i.e., 2017–2030. In 2017, the diagnosed prevalent population of low-grade NMIBC patients was 136,822 and high-grade NMIBC patients were 76,962 in the US, which is anticipated to increase in the forecast period.

Among the European 5 countries, Germany had the highest diagnosed prevalent population of NMIBC followed by Italy and Spain. On the other hand, the United Kingdom had the lowest diagnosed prevalent population of NMIBC.

For more information on Non-Muscle invasive bladder cancer (NMIBC) Market, visit:
https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market